Table 4. Total duration of antibiotic use among patients with single initial isolation of E. cloacae versus patients with serial isolation of E. cloacaea.
| Duration of Antibiotic Use, median days (IQR) | ||||
|---|---|---|---|---|
| Antimicrobials | Patients with single initial E. cloacae infection (N = 63) | Patients with serial E. cloacae infection (N = 49) | All Patients with E. cloacae isolation (N = 112) | p-value |
| Aminoglycoside | 1 (0–8) | 1 (0–4) | 1 (0–7) | 0.153 |
| Carbapenem | 12 (5–20) | 13 (4–22) | 12.5 (4–21.5) | 0.796 |
| Cephalosporin- 1st generation | 7 (3–15) | 11 (6–15) | 8.5 (4–15) | 0.052 |
| Fluoroquinolone | 7 (0–15) | 10 (3–16) | 9 (1.5–15.5) | 0.299 |
| Vancomycin | 12 (1–27) | 9 (3–28) | 10 (2–27) | 0.911 |
| Total antibiotic durationb | 39 (30–63) | 47 (35–72) | 43.5 (32.5–71.0) | 0.236 |
IQR–interquartile range
a Antibiotics that were used for a median of zero days in both groups are not shown and include aminopenicillin, anti-pseudomonal penicillin, 2nd generation cephalosporin, 3rd generation cephalosporin, 4th generation cephalosporin, clindamycin, linezolid, macrolide, monobactam, penicillin, penicillinase-resistant penicillin, polymyxin, trimethoprim-sulfamethoxazole, and topical antibiotic therapy.
b Total antibiotic duration was calculated as the total number of days at least one antibiotic was administered. Any days on which no antibiotics were administered are not counted in this measure.